In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis

被引：136

作者：

Rodríguez, JC ^{[1
]}

Ruiz, M ^{[1
]}

López, M ^{[1
]}

Royo, G ^{[1
]}

机构：

[1] Univ Miguel Hernandez, Hosp Gen Univ Elche, Sect Microbiol, Alicante 03202, Spain

来源：

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS | 2002年 / 20卷 / 06期

关键词：

Mycobaeterium tuberculosis; fluorquinolones; linezolid;

D O I：

10.1016/S0924-8579(02)00239-X

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

The in vitro activity of moxifloxacin, gatifloxacin, levofloxacin and linezolid was evaluated against 234 strains of Mycobacterium tuberculosis isolated in the Southeast of Spain. All drugs tested showed good activity, with an MIC90 of less than I mg/l, and were active against isociacide and rifampicin resistant strains. Three strains were resistant to isoniazid and to the fluoroquinolones, which suggested the existence of mechanisms of resistance not yet described. These new compounds may prove to be therapeutic alternatives for treatment of multi-resistant tuberculosis and further studies should be done to demonstrate their true usefulness. (C) 2002 Elsevier Science B.V. and International Society of Chemotherapy. All rights reserved.

引用

页码：464 / 467

页数：4

共 40 条

[1] The clinical use of fluoroquinolones for the treatment of mycobacterial diseases [J].

Alangaden, GJ ;

Lerner, SA .

CLINICAL INFECTIOUS DISEASES, 1997, 25 (05) :1213-1221

[2] CHARACTERIZATION OF FLUOROQUINOLONE-RESISTANT MUTANT STRAINS OF MYCOBACTERIUM-TUBERCULOSIS SELECTED IN THE LABORATORY AND ISOLATED FROM PATIENTS [J].

ALANGADEN, GJ ;

MANAVATHU, EK ;

VAKULENKO, SB ;

ZVONOK, NM ;

LERNER, SA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (08) :1700-1703

[3] OXAZOLIDINONES, A NEW CLASS OF SYNTHETIC ANTITUBERCULOSIS AGENT - INVITRO AND INVIVO ACTIVITIES OF DUP-721 AGAINST MYCOBACTERIUM-TUBERCULOSIS [J].

ASHTEKAR, DR ;

COSTAPERIERA, R ;

SHRINIVASAN, T ;

IYYER, R ;

VISHVANATHAN, N ;

RITTEL, W .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1991, 14 (06) :465-471

[4] PROSPECTIVE-STUDY OF DRUG-RESISTANT TUBERCULOSIS IN A SPANISH URBAN-POPULATION INCLUDING PATIENTS AT RISK FOR HIV-INFECTION [J].

AUSINA, V ;

RIUTORT, N ;

VINADO, B ;

MANTEROLA, JM ;

MANZANO, JR ;

RODRIGO, C ;

MATAS, L ;

GIMENEZ, M ;

TOR, J ;

ROCA, J .

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1995, 14 (02) :105-110

[5] Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity [J].

Barbachyn, MR ;

Hutchinson, DK ;

Brickner, SJ ;

Cynamon, MH ;

Kilburn, JO ;

Klemens, SP ;

Glickman, SE ;

Grega, KC ;

Hendges, SK ;

Toops, DS ;

Ford, CW ;

Zurenko, GE .

JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (03) :680-685

[6]

CHEN CH, 1998, AM REV RESPIR DIS, V140, P987

[7] Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections [J].

Chien, JW ;

Kucia, ML ;

Salata, RA .

CLINICAL INFECTIOUS DISEASES, 2000, 30 (01) :146-151

[8] Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model [J].

Cynamon, MH ;

Klemens, SP ;

Sharpe, CA ;

Chase, S .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (05) :1189-1191

[9]

DiPerri G, 1996, NEW ENGL J MED, V334, P268

[10] Mutant prevention concentration as a measure of antibiotic potency:: Studies with clinical isolates of Mycobacterium tuberculosis [J].

Dong, YZ ;

Zhao, XL ;

Kreiswirth, BN ;

Drlica, K .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (09) :2581-2584

← 1 2 3 4 →